CLR 131 Elicits Promising Response Rates in Triple-refractory Multiple Myeloma Trial
CLR 131, Cellectar Biosciences’ lead experimental candidate, resulted in a 40% response rate among people with multiple myeloma who failed to respond…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
‘Everybody Loves Raymond’ Cast Reunites for Virtual Fundraiser
The cast of the hit sitcom “Everybody Loves Raymond” reunited online to honor former co-star Peter Boyle for the International Myeloma Foundation’s (IMF)…
Darzalex Delays Disease Progression After ASCT, Phase 3 Trial Reports
First-line maintenance therapy with Darzalex (daratumumab) significantly delays disease progression or death in adults with multiple myeloma who responded to autologous stem cell transplant (ASCT), according to data…
Oncopeptides Will Seek Conditional Approval of Melflufen in Europe
Oncopeptides soon will seek conditional approval of melflufen (melphalan flufenamide) in the EU for the treatment of relapsed or refractory multiple myeloma. The pharmaceutical…
Sarclisa Triple Combo Conditionally Approved for NHS Use in England, Wales
After first rejecting a Sarclisa (isatuximab) triple combination therapy due to cost-effectiveness concerns, the U.K.’s National Institute for Health and Care…
1st Patient Dosed With Investigational T-cell Therapy NEXI-002 in Phase 1/2 Trial
NexImmune has dosed the first patient participating in its Phase 1/2 trial of NEXI-002, the company’s investigational T-cell therapy for multiple…
